Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchAmantadineAmantadine (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 
    
  
Amantadine for COVID-19
3 studies with >500 patients
Hospital Icon Control
Hospital Icon Amantadine Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Amantadine studies. May 2025. c19early.org
0 0.5 1 1.5+ All studies -19% Mortality -0% Hospitalization -67% Recovery 5% RCTs -19% RCT mortality -0% Late -19% Favorsamantadine Favorscontrol
Recent:
Chober
Rejdak
Weis.
Oct 31
2023
Weis et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.06.023 Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial
48% worse recovery (p=0.1). RCT 242 non-hospitalized COVID-19 patients showing no benefit of amantadine for disease progression.
Sep 14
2023
Rejdak et al., European Journal of Neurology, doi:10.1111/ene.16045 Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial
39% improved recovery (p=0.03) and 89% lower progression (p=0.12). RCT 99 patients showing higher complete recovery rates with amantadine, but no significant difference in progression. Authors suggest amantadine's central nervous system effects may have contributed to faster recovery by reducing neuropsy..
Jun 30
2023
Barczyk et al., Respiratory Medicine, doi:10.1016/j.rmed.2023.107198 Efficacy of oral amantadine among patients hospitalised with COVID-19: A randomised, double-blind, placebo-controlled, multicentre study
13% higher mortality (p=0.83) and 18% lower ICU admission (p=0.75). RCT 186 hospitalized COVID-19 patients showing no significant differences with oral amantadine compared to placebo.
Nov 30
2022
Chober et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.026 Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study
Retrospective 241 COVID-19 ICU patients requiring mechanical ventilation showing significantly lower mortality with intravenous amantadine. However the KM plot shows very high control deaths on day 1 and no treatment deaths days 2-4. Give..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit